Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 96-week Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF+FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy

Trial Profile

A 96-week Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF+FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms ADVANCE
  • Most Recent Events

    • 12 Nov 2019 Results published in the AIDS.
    • 24 Jul 2019 Primary endpoint (Proportion of patients with undetectable plasma HIV-1 RNA levels ( 50 copies/mL) at Week 48) has been met as per results published in the New England Journal of Medicine
    • 24 Jul 2019 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top